Repository logo
 

Chromosome contacts in activated T cells identify autoimmune disease candidate genes

Published version
Peer-reviewed

Type

Article

Change log

Authors

garcia, AR 
javierre, B-M 
rainbow, DB 
cairns, J 

Abstract

BACKGROUND: Autoimmune disease-associated variants are preferentially found in regulatory regions in immune cells, particularly CD4+ T cells. Linking such regulatory regions to gene promoters in disease-relevant cell contexts facilitates identification of candidate disease genes. RESULTS: Within four hours, activation of CD4+ T cells invokes changes in histone modifications and enhancer RNA transcription that correspond to altered expression of the interacting genes identified by promoter capture Hi-C (PCHi-C). By integrating PCHi-C data with genetic associations for five autoimmune diseases we prioritised 245 candidate genes with a median distance from peak signal to prioritised gene of 153 kb. Just under half (108/245) prioritised genes related to activation-sensitive interactions. This included IL2RA, where allele-specific expression analyses were consistent with its interaction-mediated regulation, illustrating the utility of the approach. CONCLUSIONS: Our systematic experimental framework offers an alternative approach to candidate causal gene identification for variants with cell state-specific functional effects, with achievable sample sizes.

Description

Keywords

Genetics, Genomics, Chromatin conformation, CD4+ T cells, CD4+ T cell activation, Autoimmune disease, Genome-wide association studies

Journal Title

Genome Biology

Conference Name

Journal ISSN

1474-7596
1474-760X

Volume Title

18

Publisher

Springer Nature
Sponsorship
WELLCOME TRUST (107881/Z/15/Z)
MRC (1185)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (U01DK062418)
Wellcome Trust (089989/Z/09/Z)
Wellcome Trust (100140/Z/12/Z)
Wellcome Trust (091157/Z/10/B)
Medical Research Council (MC_UU_00002/4)
This work was funded by the JDRF (9-2011-253), the Wellcome Trust (089989, 091157, 107881), the UK Medical Research Council (MR/L007150/1, MC_UP_1302/5), the UK Biotechnology and Biological Sciences Research Council (BB/J004480/1) and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. The research leading to these results has received funding from the European Union’s 7th Framework Programme (FP7/2007-2013) under grant agreement no. 241447 (NAIMIT). The Cambridge Institute for Medical Research (CIMR) is in receipt of a Wellcome Trust Strategic Award (100140).